

# 9<sup>TH</sup> DRESDEN SYMPOSIUM ON AUTOANTIBODIES

DRESDEN, SEPTEMBER 2–5, 2009



FINAL PROGRAMME

[www.gfid-ev.de](http://www.gfid-ev.de)

Karsten Conrad, Werner Schöblier, Falk Hiepe, Marvin J. Fritzler

Autoantibodies in Systemic  
Autoimmune Diseases  
A Diagnostic Reference



AUTOANTIGENS, AUTOANTIBODIES, AUTOIMMUNITY  
Volume 2, second Edition - 2007



PABST

2nd edition

Karsten Conrad, Werner Schöblier, Falk Hiepe,  
Marvin J. Fritzler

## **Autoantibodies in Systemic Autoimmune Diseases – A Diagnostic Reference** second Edition

Pabst Science Publishers, 2007

ISBN 978-3-89967-420-0

Autoantibodies are a very heterogeneous group of antibodies with respect to their specificity, induction, effects, and clinical significance. Testing for autoantibodies can be helpful or necessary for the diagnosis, differential diagnosis, prognostication, or monitoring of autoimmune diseases.

In case of limited (forme fruste) disease or a single disease manifestation, the detection of serum autoantibodies can play an important role in raising the suspicion of evolving disease and forecasting prognosis. This book and reference guide is intended to assist the physician in understanding and interpreting the variety of autoantibodies that are being used as diagnostic and prognostic tools for patients with systemic rheumatic diseases. Autoantibodies observed in systemic autoimmune diseases are described in alphabetical order in Part 1 of this reference guide. In Part 2, systemic autoimmune disorders as well as symptoms that indicate the possible presence of an autoimmune disease are listed. Systemic manifestations of organ-specific autoimmune diseases will not be covered in this volume. Guide marks were inserted to ensure fast and easy cross-reference between symptoms, a given autoimmune disease and associated autoantibodies. Although the landscape of autoantibody testing continues to change, this information will be a useful and valuable reference for many years to come.



Gesellschaft zur Förderung der Immundiagnostik e.V.

Dresden

<http://www.GFID-eV.de>

Dear Colleagues,

On behalf of the Organizing Committee it is a great pleasure to welcome you to the 9th Dresden Symposium on Autoantibodies.

The Symposium is organised by the Institute of Immunology of the Medical Faculty of the Technical University Dresden and the "Gesellschaft zur Förderung der Immundiagnostik e.V." (Society for the Advancement of Immune Diagnostics). The goal is to bring together clinicians and scientists specialising in "autoimmunology" to exchange academic information and to present and discuss the results of basic and applied research on autoantigens, autoantibodies and autoimmunity.

In the spectrum of immunological diseases affecting various organs by inflammation and/or fibrosis, autoimmune reactions play an important role. Based on different studies both in humans as well as in animal models it becomes obvious that there is a broad range of pathologies that involve not only "primary" autoimmune reactions but also other pathogenic mechanisms such as postinfectious and autoinflammatory processes. The heterogeneity within the immunological diseases may reflect the variable expression of autoinflammatory, autoimmune, and up to now unknown factors in disease development and manifestation. The current Dresden Symposium on Autoantibodies entitled "From Pathogenesis to Therapy of Autoimmune diseases" will focus on different aspects of the pathogenesis of autoimmune and autoimmune-like diseases, the detection of novel and the relevance of esoteric autoantibodies, and biological therapies. The clarification of the etiopathological mechanisms is required to optimize prophylaxis, diagnostics and therapy of autoimmune diseases. Especially, the application of novel and designer biological therapies needs a better understanding of the processes that are involved in the genesis of immunological diseases. Some findings of the role of epigenetic mechanisms and innate immunity in the

pathogenesis of autoimmune diseases may offer novel prophylactic and therapeutic strategies. Regardless of the underlying pathology, disease-associated autoantibodies are important biomarkers for the vast majority of non-organ and organ specific autoimmune diseases. However, to improve our understanding of these diseases and serological diagnostics it is necessary to search for novel autoantibodies, to further evaluate the real clinical relevance of known autoantibodies and to further develop and standardize the detection methods. The current symposium highlights novel insights into the immune dysregulation, pathogenesis, serological diagnostics and biological therapies of autoimmune diseases with the main focus on rheumatoid arthritis, systemic lupus erythematosus, and autoimmune neurological diseases.

We would like to express our thanks to the members of the International Advisory Board and to the active contributors who will present their latest achievements as well as to the many sponsors who enabled this symposium. We expect that our 9th Dresden Symposium on Autoantibodies will stimulate a broad debate how the new achievements from the bench work could help to improve diagnostics and therapy of autoimmune diseases. We hope that you will enjoy the scientific programme and your stay in Dresden.

With best wishes,  
Karsten Conrad  
On behalf of the Organizing Committee

<b>Registration</b>	<b>12.00–14.15</b>
<b>Welcome and Introduction</b>	<b>14.15–14.30</b>
<b>THE SPECTRUM AND PATHOGENESIS OF NONINFECTIOUS INFLAMMATORY AND SCLEROSING DISEASES</b>	<b>14.30–16.00</b>
Co-Chairs: K. Conrad (Dresden, Germany) P. von Landenberg (Olten, Switzerland)	
The autoimmune – autoinflammatory continuum <i>Michael McDermott (Leeds, UK)</i>	14.30–15.00
Autoimmune pancreatitis and IgG4-related sclerosing diseases <i>Terumi Kamisawa (Tokyo, Japan)</i>	15.00–15.30
Autoallergy – chronic inflammation by IgE autoreactivity <i>Rudolf Valenta (Vienna, Austria)</i>	15.30–16.00
COFFEE BREAK – POSTER AND EXHIBITION VIEWING	16.00–16.40
<b>BIOLOGICAL THERAPY OF AUTOIMMUNE DISEASES I</b>	<b>16.40–18.30</b>
Co-Chairs: G. Steiner (Vienna, Austria) C. Chizzolini (Geneva, Switzerland)	
Advances in targeted therapies <i>Joseph Smolen (Vienna, Austria)</i>	16.40–17.20
The role of B cells in immunoregulation <i>Elias Toubi (Haifa, Israel)</i>	17.20–17.50

WEDNESDAY  
SEPTEMBER 02

17.50–18.15

Targeting of memory plasma cells as therapeutic option  
in autoimmune diseases

*Falk Hiepe (Berlin, Germany)*

18.15–18.30

\* Peptide-based immunotherapy of dilated cardiomyopathy  
in a Lewis rat model

*Vladimir Kocoski (Würzburg, Germany)*

**18.45**

**Welcome Reception**

**PATHOGENETIC ASPECTS  
OF AUTOIMMUNE DISEASES**

Co-Chairs: F. Hiepe (Berlin, Germany)  
E. Toubi (Haifa, Israel)

The mosaic of autoimmunity – Autoantibodies, prediction  
and therapy

*Yehuda Shoenfeld (Tel-Hashomer, Israel)*

08.30–09.00

The mosaic of the etiopathogenesis of SLE –  
Role of chromatin binding autoantibodies

*Martin Herrmann (Erlangen, Germany)*

09.00–09.30

A mutation in TREX1 that impairs susceptibility  
to granzyme A mediated cell death causes familial  
chilblain lupus

*Min Ae Lee-Kirsch (Dresden, Germany)*

09.30–09.45

\* Antiphospholipid antibodies affect the process  
of angiogenesis: novel mechanism of placental damage

*Silvia d'Ippolito (Rome, Italy)*

09.45–10.00

COFFEE BREAK – POSTER AND EXHIBITION VIEWING

10.00–10.45

Poster viewing

**P1-P7** Novel autoantibodies

**P8-P11** Methodical aspects

**P12-P13** Therapy

10.45–12.30

**THE ROLE OF EPIGENETICS AND INNATE  
IMMUNITY IN THE PATHOGENESIS  
OF AUTOIMMUNE DISEASES**

Co-Chairs: E.K.L. Chan (Gainesville, USA)  
M. Herrmann (Erlangen, Germany)

10.45–11.15

Epigenetic mechanisms in the induction and aggravation  
of autoimmunity

*Olga Sánchez-Pernaute (Madrid, Spain)*

11.15–11.35

Toll-like receptors and autoimmunity

*Philipp von Landenberg (Olten, Switzerland)*

11.35–11.55

Proteinase 3 and its receptors: linking innate  
to autoimmunity in ANCA-associated vasculitides

*Elena Csernok (Lübeck, Germany)*

11.55–12.15

Antifibroblast antibodies and Toll-like receptors  
in the pathogenesis of systemic sclerosis

*Carlo Chizzolini (Geneva, Switzerland)*

12.15–12.30

\* Epigenetic regulation of IL-10 expression:  
The role of activation dependent changes in DNA  
methylation patterns in CD4+ T cell subsets

*Christian M. Hedrich (Dresden, Germany)*

12.30–13.30

LUNCH BREAK – POSTER AND EXHIBITION VIEWING

Poster viewing

**P19-P26** Vasculitides/ANCA



**NOVEL AND ESOTERIC AUTOANTIBODIES**

Co-Chairs: C. Casiano (Loma Linda, USA)  
R.L. Humbel (Luxembourg)

The clinical paradox of esoteric and novel autoantibodies  
*Marvin Fritzler (Calgary, Canada)* 13.30–14.00

Anti-RNA helicase A as a new serologic marker of early SLE  
*Minoru Satoh (Gainesville, USA)* 14.00–14.30

Identification of Rho-GTPase-activating protein  
p26 as a novel autoantigen  
*Martin Blüthner (Karlsruhe, Germany)* 14.30–14.45

Identification of the  $\beta$ - and  $\gamma$ -subunits of F1-ATPase  
as target antigens in anti-M2/PDC-E2 negative primary  
biliary cirrhosis (PBC)  
*Beate Preuß (Tübingen, Germany)* 14.45–15.00

\* Sperm-associated antigen 16 isoform 2:  
A novel candidate autoantigen in multiple sclerosis  
*Klaartje Somers (Diepenbeek, Belgium)* 15.00–15.15

Anti-p155/140 (anti-TIF1) autoantibodies in patients  
with cancer associated myositis detected in a single centre  
*Jiri Vencovsky (Prague, Czech Republic)* 15.15–15.30

COFFEE BREAK - POSTER AND EXHIBITION VIEWING 15.30–16.00

16.00–17.30

**MOLECULAR MIMICRY  
AND AUTOIMMUNE DISEASES**

Co-Chairs: Y. Shoenfeld (Tel-Hashomer, Israel)  
A. Ebringer (London, UK)

16.00–16.30

Molecular mimicry in ankylosing spondylitis  
and rheumatoid arthritis  
*Alan Ebringer (London, UK)*

16.30–17.00

Polymyalgia rheumatica, blindness and anti-Proteus  
antibodies  
*Roland Pechlaner (Innsbruck, Austria)*

17.00–17.30

\* Vaccination and autoimmunity  
*Nancy Agmon-Levin (Tel-Hashomer, Israel)*

16.30–18.30

**PRESENTATIONS OF YOUNG SCIENTISTS**

Co-Chairs: K. Conrad (Dresden, Germany)  
U. Sack (Leipzig, Germany)

16.30–16.40

\* Gender differences in oxidative stress and apoptosis  
of vascular cells induced by autoantibodies specific  
to RLIP76  
*Tania Colasanti (Rome, Italy)*

16.40–16.50

\* Immortalized B cell lines from multiple sclerosis patients  
produce antibodies that bind an oligodendrocyte precursor  
cell line  
*Judith Fraussen (Diepenbeek, Belgium)*

16.50–17.00

\* Analysis of autoantibody profiles in cerebrospinal fluid  
and serum of a relapsing-remitting MS patient with active  
disease using Serological Antigen Selection  
*Cindy Govarts (Diepenbeek, Belgium)*

- \* Anti-CENP-A and anti-CENP-B antibodies show high concordance and similar clinical associations in patients with systemic sclerosis despite completely different underlying protein sequences  
*Katharina Hanke (Potsdam, Germany)* 17.00–17.10
- \* Anti-argonaute2 (Ago2/Su) and -Ro antibodies are the common autoantibody specificities in primary anti-phospholipid syndrome (PAPS)  
*Angela Ceribelli (Brescia, Italy)* 17.10–17.20
- \*  $\beta$ 1-adrenoreceptor autoantibodies in a Lewis rat model of dilated cardiomyopathy  
*Vladimir Kocoski (Würzburg, Germany)* 17.20–17.30
- \* Heterogeneous nuclear ribonucleoproteins, novel target antigens of autoantibodies in autoimmune disease?  
*Katrijn Op De Beéck (Leuven, Belgium)* 17.30–17.40
- \* Occurrence of autoantibodies to calreticulin in oncological patients and patients from risk groups  
*Aneta Pekáriková (Prague, Czech Republic)* 17.40–17.50
- \* Technical parameters of particle array development  
*Kai Großmann (Senftenberg, Germany)* 17.50–18.00
- \* Performance evaluation of PR3-ANCA ELISAs  
*Matthew Hayman (Christchurch, New Zealand)* 18.00–18.10
- Discussion 18.10–18.30

08.30–10.00

**METHODICAL ASPECTS  
AND DIAGNOSTIC STRATEGIES I**

Co-Chairs: X. Bossuyt (Leuven, Belgium)  
A. Kromminga (Hamburg, Germany)

08.30–09.00

Recommendations of the ACR committee on the standardization of autoantibody detection  
*Pier Luigi Meroni (Milan, Italy)*

09.00–09.15

\* Detection and differentiation of non-organ specific autoantibodies by a fully automated HEp-2 cell assay  
*Rico Hiemann (Dresden, Germany)*

09.15–9.30

Contribution of immunofluorescence on formalin-fixed neutrophils in ANCA detection and differentiation  
*Elena Csernok (Lübeck, Germany)*

09.30–09.45

Peptide resolved diagnostics in systemic autoimmune diseases: Potentials and pitfalls  
*Michael Mahler (Neuss, Germany)*

09.45–10.00

Diagnosis of IgA-deficient coeliac disease by assay of IgG antibodies against deamidated gliadin (GAF3X)  
*Thomas Mothes (Leipzig, Germany)*

10.00–10.30

COFFEE BREAK – POSTER AND EXHIBITION VIEWING

10.30–12.15

**METHODICAL ASPECTS AND DIAGNOSTIC STRATEGIES II**

Co-Chairs: Y. Shoenfeld (Tel-Hashomer, Israel)  
P.L. Meroni (Milan, Italy)

10.30–11.00

Clinical performance characteristics of a laboratory test  
*Xavier Bossuyt (Leuven, Belgium)*

Stratification of autoantibody signatures in human sera by peptide epitope profiling <i>Hans-Jürgen Thiesen (Rostock, Germany)</i>	11.00–11.15
ELISA using ectodomains of desmoglein 1 and 3 expressed in HEK293 for sensitive and specific detection of pemphigus autoantibodies <i>Wolfgang Schlumberger (Lübeck, Germany)</i>	11.15–11.30
* Anti-Th/To antibodies in Italian scleroderma patients: Clinical and immunological correlations and comparison with patients with anti-centromere (ACA) antibodies <i>Angela Ceribelli (Brescia, Italy)</i>	11.30–11.45
Identification of GP2, the major zymogen granule membrane glycoprotein, as the autoantigen of pancreatic antibodies in Crohn's disease <i>Dirk Roggenbuck (Dahlewitz, Germany)</i>	11.45–12.00
ELISA for the detection of autoantibodies against DNA-bound lactoferrin in ulcerative colitis <i>Lars Komorowski (Lübeck, Germany)</i>	12.00–12.15
EASI FORUM LUNCH MEETING	12.15–13.30
LUNCH BREAK – POSTER AND EXHIBITION VIEWING	12.15–13.30
Poster viewing <b>P27-P40</b> Connective tissue diseases and APS	

13.30–14.30

**BIOLOGY OF AUTOANTIGEN/AUTOANTIBODY SYSTEMS**

Co-Chairs: M. Fritzler (Calgary, Canada)  
P. von Landenberg (Olten, Switzerland)

13.30–14.00

Inducible cytoplasmic ring/rod structures as targets of emerging human autoantibodies associated with viral infection and interferon therapy  
*Edward K.L. Chan (Gainesville, USA)*

14.00–14.15

Clinical and Autoantibodies to DFS70/LEDGF: natural antibodies or sensors of cellular stress?  
*Carlos Casiano (Loma Linda, USA)*

14.15–14.30

Circulating proteasomes and autoantibodies  
*Eugen Feist (Berlin, Germany)*

14.30–15.45

**BIOLOGICAL THERAPY OF AUTOIMMUNE DISEASES II**

Co-Chairs: E. Feist (Berlin, Germany)  
W. van Venrooij (Nijmegen, The Netherlands)

14.30–15.00

Immune reactions induced by biologicals  
*Arno Kromminga (Hamburg, Germany)*

15.00–15.15

\* Measuring anti-adalimumab levels in the presence of adalimumab  
*Pauline van Schouwenburg (Amsterdam, The Netherlands)*

15.15–15.45

Serological changes induced by B cell ablative therapy  
*Pierre Youinou (Brest, France)*

**DRESDEN PRIZE ON THE STUDY  
OF AUTOANTIBODIES**

Award Ceremony

15.45–16.00

COFFEE BREAK – POSTER AND EXHIBITION VIEWING

16.00–16.30

Poster viewing

**P41-58** Organ specific autoimmune diseases

**Departure to Weesenstein**

16.30

Guided visit of the Castle of Weesenstein

17.30

Social Dinner

18.30

08.30–10.00

### RHEUMATOID ARTHRITIS

Co-Chairs: E. Csernok (Lübeck, Germany)  
F. Hiepe (Berlin, Germany)

08.30–09.00

Clinical relevance of rheumatoid arthritis associated autoantibodies  
*Günter Steiner (Vienna, Austria)*

09.00–09.30

The rheumatic arthritis cycle  
*Walter J. van Venrooij (Nijmegen, The Netherlands)*

09.30–09.45

\* Novel autoantibody targets in early and seronegative rheumatoid arthritis  
*Klaartje Somers (Diepenbeek, Belgium)*

09.45–10.00

Development of novel antibody markers for diagnostic protein biochips – The rheumatoid arthritis case study  
*Angelika Lueking (Dortmund, Germany)*

10.00–10.30

COFFEE BREAK – POSTER AND EXHIBITION VIEWING

Poster viewing

**P14-P18** Rheumatoid arthritis

10.30–12.00

### AUTOIMMUNE NEUROLOGICAL DISEASES

Co-Chairs: K. Conrad (Dresden, Germany)  
H.J. Willison (Glasgow, UK)

10.30–11.00

Peripheral neuropathies and antiglycolipid antibodies  
*Hugh J. Willison (Glasgow, UK)*

11.00–11.30

Antiganglioside antibodies – A very heterogeneous family of biomarkers  
*René-Louis Humbel (Esch-sur-Alzette, Luxembourg)*



Recombinant immunofluorescence assay for the detection of anti-glutamate receptor (type NMDA) antibodies in the differential diagnosis of autoimmune encephalopathies

*Klaus-Peter Wandinger (Lübeck, Germany)*

11.30–11.45

Antibodies against aquaporin-4 in neuromyelitis optica: cell-based assay vs. immunoprecipitation assay

*Dörte Hamann (Amsterdam, The Netherlands)*

11.45–12.00

\* The lectures marked with asterisks are given by the candidates for the DRESDEN PRIZE ON THE STUDY OF AUTOANTIBODIES.

WEDNESDAY,  
SEPTEMBER 02  
(16.00 p.m.)  
UNTIL  
SATURDAY,  
SEPTEMBER 05  
(10.30 a.m.)

## POSTER EXHIBITION

### Novel autoantibodies

**P1** Systematic development of novel antibody markers for diagnostic protein biochips – the prostate cancer case study  
*A. Kowald, G. Bartsch, H. Klocker, J. Beator, S. Müllner, A. Lueking (Düsseldorf, Germany)*

**P2** Anti-p155/140 (anti-TIF1) autoantibodies in patients with cancer associated myositis detected in a single centre  
*J. Vencovský, H. Mann, I. Půtová, Z. Betteridge, H. Gunawardena, N. McHugh (Prague, Czech Republic)*

**P3** The cell cycle protein Nop52 is a candidate target autoantigen  
*A. Swart, M. Mahler, M.J. Fritzler (Neuss, Germany)*

**P4** Identification of inosine-1,2-monophosphate-dehydrogenase-2 as a novel autoantigen  
*M. Blüthner, H. Appelhans, I. Moosbrugger, C. Wiemann, D. Lenz, H.P. Seelig (Karlsruhe, Germany)*

**P5** Heterogeneous nuclear ribonucleoproteins, novel target antigens of autoantibodies in autoimmune disease?  
*K. Op De Beéck, K. Van den Bergh, L. Maes, G. Michiels, P. Verschueren, R. Westhovens, D. Blockmans, X. Bossuyt (Leuven, Belgium)*

**P6** New autoantibodies in primary sclerosing cholangitis: reactivity with distinct immunodominant epitopes of sulfite oxidase  
*B. Preuß, C. Berg, F. Altenberend, M. Gregor, S. Stevanovic, R. Klein (Tübingen, Germany)*

**P7** Sperm-associated antigen 16 isoform 2: A novel candidate autoantigen in multiple sclerosis  
*K. Somers, R. Hupperts, C. Zwanikken, P. Stinissen, V. Somers (Limburg, Belgium)*

## Methodical aspects

**P8** Laboratory policies on the management of autoimmune diseases in a cohort of Italian laboratories

*A. De Nicolo, M. Tampoia and Study investigators (Bari, Italy)*

**P9** ELISA using ectodomains of desmoglein 1 and 3 expressed in HEK293 for sensitive and specific detection of pemphigus autoantibodies

*C. Dähnrich, A. Rosemann, C. Probst, L. Komorowski, W. Schlumberger, W. Stöcker, A. Recke, C. Rose, D. Zillikens, E. Schmidt (Lübeck, Germany)*

**P10** Bioplex™2200 multiplex ANAscreen assay: a novel approach for the detection of antinuclear autoantibodies

*S. Ignorini, L. Lattuada, R. Colombo (Brescia, Italy)*

**P11** Comparison of light sources for measurement of single and multiplex bead assays

*K. Großmann, A. Böhm, J. Nitschke, R. Hiemann, P. Schierack, C. Schröder, K. Conrad, U. Sack (Senftenberg, Germany)*

## Therapy

**P12** Corticosteroid-induced spinal epidural lipomatosis in the pediatric patients with chronic autoimmune disorders

*J.C. Moeller, G. Hahn, F. Pessler (Dresden, Germany)*

**P13** Measuring anti-adalimumab levels in the presence of adalimumab

*P. van Schouwenburg, G. Wolbink, L. Aarden, D. Wouters (Amsterdam, The Netherlands)*

WEDNESDAY,  
SEPTEMBER 02  
(16.00 p.m.)  
UNTIL  
SATURDAY,  
SEPTEMBER 05  
(10.30 a.m.)

### **Rheumatoid arthritis**

**P14** Novel Autoantibody targets in early and seronegative rheumatoid Arthritis

*K. Somers, P. Geusens, M. Coenen, M. Blom, P. Stinissen, V. Somers (Limburg, Belgium)*

**P15** Development of novel antibody markers for diagnostic protein biochips – the rheumatoid arthritis case study

*A. Lueking, A. Kowald, M. Schneider, H.E. Meyer, J. Beator, S. Müllner (Düsseldorf, Germany)*

**P16** Autoantibody production in early undifferentiated arthritis

*O. Abade, I. Abreu, F. Pimentel, M. Parente, J. Vaz Patto, R. Figueiredo, D. Ligeiro, C. Miguel, A. Teixeira, H. Trindade (Lisboa, Portugal)*

**P17** Diagnostic sensitivity and specificity for rheumatoid arthritis by the bio-rad kallestad ANTI-CCP II assay

*C. Lingenfelter, S. Merrill, C. Nuun, D. Atkinson, X. Guo, W. Kumpf, T. Prestigiacomo (Hercules, USA)*

**P18** Comparison of the research-based anti-Sa with the EUROIMMUN commercial anti-Sa ELISA to monitor rheumatoid arthritis activity

*M. Lora, J. Rotman, H.A. Ménard, D. Kast, C. Daehnrich, W. Stoecker, W. Schlumberger (Lübeck, Germany)*

### **Vasculitides/ANCA**

**P19** Gender differences in oxidative stress and apoptosis of vascular cells induced by autoantibodies specific to RLIP76

*T. Colasanti, P. Margutti, P. Matarrese, F. Delunardo, B. Ascione, D. Vacirca, W. Malorni, E. Ortona (Rome, Italy)*

**P20** Clinical relevance of ANCA in routine care

*Y. Ben Haj Hmida, D. Bouzid, S. Boukthir, M. Ben Ayed, H. Masmoudi (Sfax, Tunisia)*

**P21** ANCA or other neutrophil specific antibodies (NSA)

*L. Cebecauer, V. Král, J. Lupač, I. Lochman (Piešťany, Slovak Republic)*

**P22** Autoimmunity in patients with anti-neutrophil cytoplasmic antibodies: retrospective analysis of an Italian cohort of ANCA positive patients

*C. Defendenti, M. Francesca Spina, M. Longo, S. Bollani, A. Cereda, S. Saibeni, A. Reina, G. Guercilena, S. Bruno, M. Saudelli, F. Atzeni, P. Sarzi-Puttini (Milan, Italy)*

**P23** A novel immunofluorescence assay for the differentiation of pANCA and ANA

*I. Knütter, T. Büttner, J. Scholka, D. Roggenbuck, U. Anderer (Dahlewitz, Germany)*

**P24** Performance evaluation of PR3-ANCA ELISAs

*M.W. Hayman, C. Slade, K. Chamberlain, N. Cook, M.B. Spellerberg, J.L. O'Donnell (Christchurch, New Zealand)*

**P25** A novel PR3-ANCA ELISA with a mixture of human purified and recombinant PR3 as solid-phase antigen

*A. Radice, L. Bianchi, A. Palumbo, R.A. Sinico (Milan, Italy)*

**P26** High sensitive detection of autoantibodies to proteinase 3 (PR3) – a novel third generation capture ELISA

*D. Roggenbuck, T. Büttner, L. Hoffmann, H. Schmechta, D. Reinhold, K. Conrad (Dahlewitz, Germany)*

**Connective tissue diseases and APS**

**P27** VEGF gene polymorphisms in patients with systemic Lupus erythematosus

*L. Ostanek, D. Bobrowska-Snarska, M. Ostanek, A. Bińczak-Kuleta, A. Ciechanowicz, M. Brzosko (Szczecin, Poland)*

WEDNESDAY,  
SEPTEMBER 02  
(16.00 p.m.)  
UNTIL  
SATURDAY,  
SEPTEMBER 05  
(10.30 a.m.)

**P28** Anti-IFI16 autoantibodies: A new marker in autoimmunity

*S. Costa, M. Mondini, V. Caneparo, Italian FIRMA Group, S. Landolfo, M. Gariglio (Turin, Italy)*

**P29** Evaluation of a novel dsDNA ELISA for SLE disease activity measurement

*M. Mahler, M. van Liempt, J. Schulte-Pelkum, S. Schneider, T. Alexander, A. Kromminga, M. Fooke, F. Hiepe (Neuss, Germany)*

**P30** Effect of antigen affinity and isotype specificity on the diagnostic efficiency of anti-dsDNA autoantibody tests in systemic Lupus erythematosus patients

*B. Schlüter, G. Bonsmann, M. Gaubitz, P. Willeke (Münster, Germany)*

**P31** Current status of anti-dsDNA antibody diagnostics in the hospital Laborverbund

*R. Tripmacher, C. Kuznia, D. Roggenbuck, T. Büttner, B. Radau, K. Conrad, V. Jansen (Bernau, Germany)*

**P32** Anti-actinin antibodies in systemic lupus erythematosus

*Y. Thabet, A. Achour, A. Mankai, W. Sakly, Y. Renaudineau, P. Youinou, I. Chedira (Monastir, Tunisia)*

**P33** Decreased nucleosome releasing factor activity in patients with systemic lupus erythematosus

*F. Stephan, R. Manoe, B. Zwart, I. Bulder, L. Aarden, S. Zeerleder (Amsterdam, The Netherlands)*

**P34** Anti-Th/To antibodies in Italian scleroderma patients: Clinical and immunological correlations and comparison with patients with anti-centromere (ACA) antibodies

*A. Ceribelli, I. Cavazzana, P. Airò, A. Tincani, F. Franceschini, B.A. Pauley, E.K.L. Chan, M. Satoh (Brescia, Italy)*

**P35** Anti-CENP-A and anti-CENP-B antibodies show high concordance and similar clinical associations in patients with systemic sclerosis despite completely different underlying protein sequences

*K. Hanke, C.S. Brueckner, M. Becker, W. Meyer, W. Schlumberger, G. Riemekasten (Berlin, Germany)*

**P36** Evaluation of the in-house developed dot-blot and ELISA for the detection of anti-PM/scl100 autoantibodies in systemic autoimmune diseases

*L. Maes, K. Op De Beéck, K. Van Den Bergh, P. Verschueren, R. Westhovens, B. Blockmans, M. Mahler, X. Bossuyt (Leuven, Belgium)*

**P37** Anti-PM/ScI-antibodies in systemic sclerosis: Comparison between PM1-Alpha ELISA and a line assay with recombinant PM/ScI-75c and PM/ScI-100

*M. Mahler, M. Siegemund, W. Meyer, M. Petschinka, M. J. Fritzler (Neuss, Germany)*

**P38** Anti-argonaute2 (Ago2/Su) and -Ro antibodies are the common autoantibody specificities in primary anti-phospholipid syndrome (PAPS)

*A. Ceribelli, I. Cavazzana, A. Tincani, F. Franceschini, B.A. Pauley, J.Y.F. Chan, E.K.L. Chan, M. Satoh (Brescia, Italy)*

**P39** The antiphospholipid syndrome in acute ischemic stroke patients with insulinresistance

*O. Virstyuk, R.D. Gerasymchuk, N. Virstyuk, R. Portyuk (Ivano-Frankivsk, Ukraine)*

**P40** The antiphospholipid antibodies in patients with chronic heart failure

*N. Virstyuk, V. Neyko, E. Cherkachuna, O. Virstyuk (Ivano-Frankivsk, Ukraine)*

WEDNESDAY,  
SEPTEMBER 02  
(16.00 p.m.)  
UNTIL  
SATURDAY,  
SEPTEMBER 05  
(10.30 a.m.)

### Organ specific autoimmune diseases

**P41** Immortalized B cell lines from multiple sclerosis patients produce antibodies that bind an oligodendrocyte precursor cell line

*J. Fraussen, K. Vrolix, P. Martinez-Martinez, M. Losen, R. Hupperts, A. Van Diepen, R. Medaer, B. Van Wijmeersch, E. Meulemans, M.H. De Baets, P. Stinissen, V. Somers (Limburg, Belgium)*

**P42** Analysis of autoantibody profiles in cerebrospinal fluid and serum of a relapsing-remitting MS patient with active disease using serological antigen selection

*C. Govarts, K. Somers, R. Hupperts, P. Jongen, P. Stinissen, V. Somers (Limburg, Belgium)*

**P43** Anti-tau antibodies in patients with multiple sclerosis

*J. Švarcová, L. Fialová, A. Bartos, L. Cechova, D. Dolezil, I.M. Malbohan (Prague, Czech Republic)*

**P44** Avidity of antibodies against tau protein in patients with multiple sclerosis

*L. Fialová, J. Švarcová, A. Bartos, I.M. Malbohan (Prague, Czech Republic)*

**P45** Detection of antibodies to aquaporin-4 by indirect immunofluorescence employing a standardized recombinant target antigen

*S. Jarius, C. Probst, K. Borowski, D. Franciotta, B. Wildemann, W. Stöcker, K.P. Wandinger (Lübeck, Germany)*

**P46** Recombinant immunofluorescence assay for the detection of anti-glutamate receptor (type NMDA) antibodies in the differential diagnosis of autoimmune encephalopathies

*K.P. Wandinger, J. Dalmau, K. Borowski, C. Probst, K. Fehner, W. Stöcker (Lübeck, Germany)*



**P47** Co-occurrence of serum anti-ganglioside antibodies and microbial infection in patients with inflammatory peripheral neuropathy

*I. Janatkova, K. Malickova, A. Potmesilova, B. Potuznikova, T. Fucikova (Prague, Czech Republic)*

**P48** Ganglioside antibodies in amyotrophic lateral sclerosis

*U. Wurster, K. Kollwe, B. Mohammadi, T. Sinzenich, S. Petri (Hannover, Germany)*

**P49** TSH receptor antibody (TRAb) assays using human monoclonal autoantibody M22 are more sensitive than bovine TSH based assays

*K. Zöphel, P. von Landenberg, D. Roggenbuck, G. Wunderlich, T. Grüning, J. Kotzerke, K.J. Lackner, B. Rees Smith (Dresden, Germany)*

**P50** Prevalence of ovarian antibodies in women with unexplained recurrent pregnancy loss

*M. Cojocar, I.M. Cojocar, I. Silosi, S. Rogoz (Bucharest, Romania)*

**P51** Validation of Bio-Rad gastrointestinal assays for use on the EVOLISTM and EVOLISTM Twin Plus systems

*X. Guo, R. Lerner, L. Sana, W. Kumpf, T. Prestigiacomo (Hercules, USA)*

**P52** Antibodies against deamidated gliadin as a novel serologic marker for celiac disease

*M. Miler, A. Tesija Kuna, O. Zaja Franulovic, N. Vrkic (Zagreb, Croatia)*

**P53** Deamidated gliadin antibodies facilitate diagnosis in celiac disease

*T. Krieger, F. Haag (Hamburg, Germany)*

WEDNESDAY,  
SEPTEMBER 02  
(16.00 p.m.)  
UNTIL  
SATURDAY,  
SEPTEMBER 05  
(10.30 a.m.)

**P54** Diagnosis of IgA-deficient coeliac disease by assay of IgG antibodies against deamidated gliadin (GAF3X)

*D. Villalta, E. Tonutti, C. Prause, S. Koletzko, M. Stern, M.W. Laass, H.H. Uhlig, H.J. Ellis, P.J. Ciclitira, T. Richter, C. Daehnrich, W. Schlumberger, T. Mothes*

**P55** Use of recombinant autoantigens in profiling of PBC associated antibodies

*A. Neiningner, J. Kaiser, J. Weyand, C. Berg, S. Buck, R. Klein, H. Haubruck, B. Liedvogel (Freiburg, Germany)*

**P56** Autoantibodies to asialoglycoprotein receptor (ASGPR) measured by a novel ELISA - revival of a disease-activity marker in autoimmune hepatitis (AIH)

*G. Hausdorf, E. Feist, K. Conrad, D. Roggenbuck, T. Büttner, C. Berg, R. Klein (Berlin, Germany)*

**P57** Antineutrophil cytoplasmic antibodies and HLA II in Ulcerative Colitis Tunisian patients

*D. Bouzid, Y. Ben Haj Hmida, A. Amouri, N. Mahfouth, A. Kammoun, M. Ben Ayed, H. Makni, N. Tahri, H. Masmoudi (Sfax, Tunisia)*

**P58** Fine specificity of serum IgA and IgG autoantibodies against calreticulin in oncological patients

*D. Sánchez, A. Pekáriková, L. Palová-Jelínková, T. Mothes, H. Tlaskalová-Hogenová, L. Tučková (Prague, Czech Republic)*

The modern Lecture Hall Centre of the Technical University of Dresden is located on the University Campus in the South of the city, about 15 minutes walk away from the Central Railway Station.

Address of the congress venue:  
Hörsaalzentrum der Technischen Universität Dresden  
Bergstrasse 64, 01069 Dresden

September 02: 12.00 - 21.30  
September 03: 08.00 - 19.00  
September 04: 08.00 - 16.30  
September 05: 08.00 - 12.30

Phone +49 351 463 48812 and +49-160 98 35 87 47  
Fax +49 351 463 48814

Karsten Conrad, Germany

Edward K.L. Chan, USA  
Marvin Fritzler, Canada  
René-Louis Humbel, Luxembourg  
Yehuda Shoenfeld, Israel  
Philipp von Landenberg, Switzerland

Carlo Chizzolini, Switzerland  
Elena Csernok, Germany  
Falk Hiepe, Germany  
Arno Kromminga, Germany  
Pier Luigi Meroni, Italy  
Günter Steiner, Austria  
Walter J. van Venrooij, The Netherlands  
Hugh J. Willison, UK  
Pierre Youinou, France

English, no simultaneous translation

## Venue

## Registration office

## Phone/Fax on site

## Chairman

## Co-Chairmen

## International Advisory Board

## Language

**Organization**  
(Registration,  
Reservation,  
Exhibition)

Silke Zwjatkow  
GFID e.V.  
Veilchenweg 28  
D-01326 Dresden  
Phone +49 351 26 32 279  
Fax +49 351 26 32 280  
e-mail: kontakt@gfid-ev.de

**Registration fee**  
(on site)

Participants	EUR 420
GFID members	EUR 350
Students/Residents	EUR 220
One day tickets	EUR 140

(includes unlimited access to all scientific sessions, welcome reception, industrial exhibition, conference book = 6th volume of the book series "Autoantigens, Autoantibodies, Autoimmunity", coffee and lunch breaks)

Members of the Dresden University are free of charge.

**Social programme**

Wednesday,  
September 02, 2009  
18.45

Friday,  
September 04, 2009  
16.30

**Welcome reception** in the Lecture Hall Center of the Technical University of Dresden

**Guided visit and Social Dinner in the Castle of Weesenstein (90 €)**

Weesenstein Castle in the Müglitztal valley is one of the most beautiful tourist destinations before the gates of Dresden. The 700-year-old castle on a rock above the village presents its visitors Saxon history from the Middle Ages through to the 19th century. Especially delightful is a walk in the castle gardens. For more information, please see [www.schloss-weesenstein.de](http://www.schloss-weesenstein.de).

16.30: Departure by bus starting from the congress venue

17.30: Guided visit of the Castle of Weesenstein

18.30: Social Dinner

**We hope to welcome you again at our 10th Dresden Symposium on Autoantibodies, September 22–25, 2011.**

The following companies participate in the industrial exhibition and/or have made a generous sponsoring (in alphabetical order):

**A. MENARINI DIAGNOSTICS DEUTSCHLAND.**

Division der BERLIN-CHEMIE AG (Berlin, Germany)  
[www.menarini.com](http://www.menarini.com)

**Abbott GmbH & Co KG** (Wiesbaden, Germany)

[www.abbottdiagnostics.de](http://www.abbottdiagnostics.de)

**Aesku.Diagnostics e.K.** (Wendelsheim, Germany)

[www.aeskulab.com](http://www.aeskulab.com)

**Beckman Coulter GmbH** (Krefeld, Germany)

[www.beckmancoulter.com](http://www.beckmancoulter.com)

**Bio-Rad Laboratories, Inc.** (Hercules, USA)

[www.bio-rad.com](http://www.bio-rad.com)

**BioSystems S.A.** (Barcelona, Spain)

[www.biosystems.com](http://www.biosystems.com)

**Bühlmann Laboratories** (Schönenbuch, Switzerland)

[www.buhlmannlabs.ch](http://www.buhlmannlabs.ch)

**Diarect AG** (Freiburg, Germany)

[www.diarect.com](http://www.diarect.com)

**DLD Diagnostika GmbH** (Hamburg, Germany)

[www.dld-diagnostika.de](http://www.dld-diagnostika.de)

**Dr. Fooke Laboratorien GmbH** (Neuss, Germany)

[www.fooke-labs.de](http://www.fooke-labs.de)

**EUROIMMUN Medizinische Labordiagnostika AG**

(Lübeck, Germany)

[www.euroimmun.de](http://www.euroimmun.de)

**GA Generic Assays GmbH** (Dahlewitz, Germany)  
[www.genericassays.com](http://www.genericassays.com)

**hospital Laborverbund Brandenburg Berlin GmbH**  
(Bernau, Germany)  
[www.labor-bernaue.de](http://www.labor-bernaue.de)

**HUMAN GmbH** (Wiesbaden, Germany)  
[www.human.de](http://www.human.de)

**Instrumentation Laboratory GmbH** (Kirchheim, Germany)  
[www.il-ger.de](http://www.il-ger.de)

**Medical and Biological Laboratories Co., Ltd.**  
(Nagoya, Japan)  
[www.mbl.co.jp](http://www.mbl.co.jp)

**Medipan GmbH** (Dahlewitz, Germany)  
[www.medipan.de](http://www.medipan.de)

**Mikrogen GmbH** (Neuried, Germany)  
[www.mikrogen.de](http://www.mikrogen.de)


**ORGENTEC Diagnostika GmbH** (Mainz, Germany)  
[www.orgentec.com](http://www.orgentec.com)

**Phadia GmbH** (Freiburg, Germany)  
[www.phadia.com](http://www.phadia.com)

**Roche Pharma AG** (Grenzach-Wyhlen, Germany)  
[www.roche.com](http://www.roche.com)

**The Binding Site GmbH** (Schwetzingen, Germany)  
[www.bindingsite.com](http://www.bindingsite.com)

**We thank these companies for helping to make this symposium successful.**



# Three Technologies, One Solution

**IFA, EIA, Multiplex**

From the reknown Kallestad™ IFA products to the revolutionary BioPlex™ 2200, Bio-Rad provides laboratories and clinicians with innovative solutions.

**BIO-RAD**